Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: Scientific rationale and study design

Clinical Genitourinary Cancer

Volumn 4, Issue 4, 2006, Pages 299-302

  Beekman, Kathleen W ^a   Colevas, A Dimitrios ^b   Cooney, Kathleen ^a   DiPaola, Robert ^c   Dunn, Rodney L ^a   Gross, Mitchell ^d   Keller, Evan T ^a   Pienta, Kenneth J ^a   Ryan, Charles J ^e   Smith, David ^a   Hussain, Maha ^a  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^d Louis Warschaw Prostate Cancer Center   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Angiogenesis; EMD121974; Hormone refractory disease; NSC 707544; Prostate specific antigen

Indexed keywords

ANDROGEN; CILENGITIDE; CYTOKINE; ENDOTHELIAL CELL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR; INTEGRIN; NSC 707544; PROSTATE SPECIFIC ANTIGEN; VASCULOTROPIN;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ENDOTHELIUM CELL; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PHASE 2 CLINICAL TRIAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; TUMOR VASCULARIZATION;

EID: 33646859981     PISSN: 15587673     EISSN: None     Source Type: Journal    
DOI: 10.3816/CGC.2006.n.012     Document Type: Article

References (21)

1. Smith MR, Kabbinavar F, Saad F, et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol 2005; 23:2918-2925.
2. Tantivejkul K, Kalikin LM, Pienta KJ. Dynamic process of prostate cancer metastasis to bone. J Cell Biochem 2004; 91:706-717.
3. Pidgeon GP, Tang K, Cai YL, et al. Overexpression of platelet-type 12-lipoxygenase promotes tumor cell survival by enhancing alpha(v)beta(3) and alpha(v)beta(5) integrin expression. Cancer Res 2003; 63:4258-4267.
4. Eliceiri BP, Cheresh DA. The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development. J Clin Invest 1999; 103:1227-1230.
5. Giancotti FG, Ruoslahti E. Integrin signaling. Science 1999; 285:1028-1032.
6. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994; 264:569-571.
7. Schmelz M, Cress AE, Scott KM, et al. Different phenotypes in human prostate cancer: alpha6 or alpha3 integrin in cell-extracellular adhesion sites. Neoplasia 2002; 4:243-254.
8. Fornaro M, Manzotti M, Tallini G, et al. Beta1C integrin in epithelial cells correlates with a nonproliferative phenotype: forced expression of beta1C inhibits prostate epithelial cell proliferation. Am J Pathol 1998; 153:1079-1087.
9. Bello-DeOcampo D, Kleinman HK, Deocampo ND, et al. Laminin-1 and alpha6beta1 integrin regulate acinar morphogenesis of normal and malignant human prostate epithelial cells. Prostate 2001; 46:142-153.
10. Hao J, Jackson L, Calaluce R, et al. Investigation into the mechanism of the loss of laminin 5 (alpha3beta3gamma2) expression in prostate cancer. Am J Pathol 2001; 158:1129-1135.
11. Shen X, Falzon M. Parathyroid hormone-related protein upregulates integrin expression via an intracrine pathway in PC-3 prostate cancer cells. Regul Pept 2003; 113:17-29.
12. Chellaiah MA, Hruska KA. The integrin alpha(v)beta(3) and CD44 regulate the actions of osteopontin on osteoclast motility. Calcif Tissue Int 2003; 72:197-205.
13. Keller ET, Brown J. Prostate cancer bone metastases promote both osteolytic and osteoblastic activity. J Cell Biochem 2004; 91:718-729.
14. Dechantsreiter MA, Planker E, Matha B, et al. N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists. J Med Chem 1999; 42:3033-3040.
15. Simon R, Wittes RE, Ellenberg SS. Randomized phase II clinical trials. Cancer Treat Rep 1985; 69:1375-1381.
16. Carducci MA, Padley RJ, Breul J, et al. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol 2003; 21:679-689.
17. Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999; 17:3461-3467.
18. Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004; 351:781-791.
19. Larson CJ, Moreno JG, Pienta KJ, et al. Apoptosis of circulating tumor cells in prostate cancer patients. Cytometry A 2004; 62:46-53.
20. O'Hara SM, Moreno JG, Zweitzig DR, et al. Multigene reverse transcription-PCR profiling of circulating tumor cells in hormone-refractory prostate cancer. Clin Chem 2004; 50:826-835.
21. Dai J, Kitagawa Y, Zhang J, et al. Vascular endothelial growth factor contributes to the prostate cancer-induced osteoblast differentiation mediated by bone morphogenetic protein. Cancer Res 2004; 64:994-999.